Related references
Note: Only part of the references are listed.Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Factor Villa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
Takehisa Kitazawa et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors
Midori Shima et al.
BLOOD ADVANCES (2017)
A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects
Naoki Uchida et al.
BLOOD (2016)
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
Midori Shima et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation
A. Muto et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
A specific antidote for dabigatran: functional and structural characterization
Felix Schiele et al.
BLOOD (2013)
Guidelines for the management of hemophilia
A. Srivastava et al.
HAEMOPHILIA (2013)
Factor VIII inhibitors in hemophilia A: rationale and latest evidence
Char Witmer et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
Takehisa Kitazawa et al.
NATURE MEDICINE (2012)
A survey of adherence to haemophilia therapy in six European countries: results and recommendations
P. De Moerloose et al.
HAEMOPHILIA (2008)
Parents of children with haemophilia - a transforming experience
K. Beeton et al.
HAEMOPHILIA (2007)
Share Paper
